Andreas Menrad joins Ablynx as CSO
This article was originally published in Scrip
Belgium's Ablynx has appointed Dr Andreas Menrad, who has over 20 years' experience in the pharmaceutical and biotech industries, chief scientific officer. Dr Menrad previously served at Genzyme for five years, most recently as general manager and vice-president of antibody therapeutics.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.